Additionally, we experimentally demonstrate that OC2 acts as a survival factor in SCLC cell lines and its inhibition with a small molecule inhibitory drug might be a potential therapeutic strategy in this highly lethal cancer type. This evidence concerns the gene ONECUT2 and cancer.